Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics to $72 from $86 and keeps a Buy rating on the shares. The firm said the company’s 2Q24 earnings report had positive pipeline updates with programs largely on track.